Each week we will aim to bring out a concise email that provides 4-5 key pieces of information addressing a specific issue in clinical therapeutics.
This week: Psoriasis (Part 2)
Judith Atallah, Clinical Pharmacist, Ward MM
- SCALP PSORIASIS. Topical corticosteroids are the primary topical agents used for psoriasis on the scalp . Support for the use of these agents is evident in a systematic review of randomized trials that found very potent or potent topical corticosteroids were more effective treatments for scalp psoriasis than topical vitamin D analogs.
- LOCALISED PUSTULAR PSORIASIS (PALMS and SOLEs) is difficult to treat. Approaches include potent topical corticosteroids and topical bath psoralen plus UVA phototherapy.
- NAIL PSORIASIS. Although nail involvement alone is uncommon, many patients with psoriasis have disease that involves the nails.
- ERYTHRODERMIC PSORIASIS. Infliximab has data showing it to be effective for the treatment of erythrodermic psoriasis. Etanercept was effective in an open-label study of 10 patients and case reports have documented successful treatment with adalimumab and ustekinumab.
- TOPICAL tacrolimus 0.1% and pimecrolimus 1% are effective in the treatment of psoriasis.
- Hydration and emollients are valuable and inexpensive adjuncts to psoriasis treatment. Keeping psoriatic skin soft and moist minimizes the symptoms of itching and tenderness.
Please consider these issues when preparing or interpreting RMMR reports or education sessions. Contributions of content or suggested topics are welcome and should be sent directly to firstname.lastname@example.org.